Overview
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Eligibility
Inclusion Criteria:
- The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
- The subject or their legal representative agrees to participate in this study and signs a written ICF.
- The subjects are willing and able to follow planned visits and procedures.
Exclusion Criteria:
- None